Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations-Reference-Cited by-同舟云学术

Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations

Published:2021-08 Issue:22 Volume:17 Page:2867-2881
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Winfree Katherine B¹^ORCID,Molife Cliff¹^ORCID,Peterson Patrick M¹^ORCID,Chen Yongmei¹,Visseren-Grul Carla M¹^ORCID,Leusch Mark S¹^ORCID,Beyrer Julie¹^ORCID,Dimou Anastasios²^ORCID

Affiliation:

1. Lilly Corporate Center, Eli Lilly & Company, Indianapolis, IN 46285, USA

2. Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA

Abstract

Aim: To estimate real-world (rw) outcomes for first-line therapy in patients with advanced EGF receptor ( EGFR)-mutated non-small-cell lung cancer (NSCLC), focusing on specific mutation types. Patients & methods: Retrospective observational study (n = 244 patients). Results: Univariate/multivariate analyses showed longer rw progression-free survival (rwPFS) and rwPFS2 in patients with ex19del versus Leu858Arg mutations. Median overall survival was 12.3 months longer with ex19del versus Leu858Arg mutations (HR: 1.47 [95% CI: 0.96–2.25]; p = 0.074). With EGFR-tyrosine kinase inhibitor monotherapy, unadjusted rwPFS for ex19del mutations was longer than for Leu858Arg mutations (HR: 1.62 [95% CI: 1.03–2.56]; p = 0.036). Conclusion: In this rw cohort of patients with advanced EGFR+ NSCLC, ex19del mutations conferred a prognostic advantage over Leu858Arg mutations, with significantly better rwPFS and rwPFS2.

Funder

Eli Lilly and Company,

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2021-0218

Reference36 articles.

1. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2. Overview of current systemic management of EGFR-mutant NSCLC

3. The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Distinguishing EGFR mutation molecular subtypes based on MRI radiomics features of lung adenocarcinoma brain metastases;Clinical Neurology and Neurosurgery;2024-05

2. Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors;Frontiers in Oncology;2024-04-18

3. Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer;Investigational New Drugs;2024-03-27

4. Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study;BMC Cancer;2024-01-12

5. The importance of re-biopsy in the era of molecular therapy for lung cancer;Srpski arhiv za celokupno lekarstvo;2024